Description of Research Expertise:
Justin E. Bekelman, M.D., is Associate Professor in the Departments of Radiation Oncology and Medical Ethics and Health Policy at the Perelman School of Medicine, Executive Director of the Penn Center for Cancer Care Innovation at the Abramson Cancer Center, Faculty in the Center for Health Incentives and Behavioral Economics, and Senior Fellow at the Penn Center for Precision Medicine and the Leonard Davis Institute for Health Economics, all at the University of Pennsylvania. Dr. Bekelman leads research programs in cancer comparative effectiveness and delivery system and payment reform, integrating methods from the fields of epidemiology, clinical trials, health economics and public policy. In his delivery system and payment reform research, Dr. Bekelman leads a series of experimental, quasi-experimental and observational studies to evaluate the impact of new payment models and financial and non-financial strategies to improve the quality, outcomes and affordability of cancer treatments and reduce unnecessary variation in clinical practice. In his comparative effectiveness research, Dr. Bekelman leads the multi-institution Radiation Comparative Effectiveness Consortium (RADCOMP) pragmatic randomized clinical trial network for breast cancer, and co-leads the PARTIQoL randomized clinical trial for prostate cancer. Dr. Bekelman's research has appeared in scientific journals such as the Journal of the American Medical Association and the Journal of Clinical Oncology and has been featured in the mainstream media, including the New York Times, the Wall Street Journal, National Public Radio, and news outlets in Canada and Europe. He has received research funding from the National Cancer Institute, the Patient-Centered Outcomes Research Institute (PCORI), the American Cancer Society, and philanthropic sources. Dr. Bekelman has served as an advisor to the National Cancer Institute on clinical trial policy and to the Centers for Medicare & Medicaid Services on cacner care payment reform.
Dr. Bekelman completed his undergraduate studies at Princeton University in the Woodrow Wilson School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Previously, he was a management consultant at the Kalchas Group, advising senior executives of health care and insurance clients on corporate strategy. Dr. Bekelman also served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.
Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Schroeck FR, Bekelman JE, Kahn JM, Nelson JB, Barnato AE: The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer
Cancer : 2017. In press.
Guttman DM, Mitra N, Bekelman J, Metz JM, Plastaras JP, Feng W, Swisher-McClure S: Improved overall survival with aggressive primary tumor radiotherapy for patients with metastatic esophageal cancer Journal of Thoracic Oncology : 2017. In press.
Radhakrishnan A, Grande D, Mitra N, Bekelman J, Stillson C, Pollack CE: Second opinions from urologists for prostate cancer: who gets them, why, and their link to treatment Cancer 123 (6): 1027-1034,2017.
Narayan V, Vapiwala N, Mick R, Subramanian P, Christodouleas JP, Bekelman JE, Deville C, Ranendran R, Haas NB: Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following
Prostatectomy Int J Radiat Oncol Biol Phys 97 (2): 355-361,2017.
Pollack CE, Ross ME, Armstrong K, Branas CC, Rhodes KV, Bekelman JE, Wentz A, Stillson C, Radhakrishnan A, Oyeniran E, Grande D: Using a Mystery-Caller Approach to Examine Access to Prostate Cancer Care in Philadelphia Plus One 11 (10): e0164411,2016.
Journy N, Morton LM, Kleinerman RA, Bekelman JE, Berrington de Gonzalez A: Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer JAMA Oncol 2 (10): 1368-1370,2016.
Bekelman JE, Halpern SD, Blankart CR, Bynum JP, Cohen J, Fowler R, Kaasa S, Kwietniewski L, Melberg HO, Onwuteaka-Philipsen B, Oosterveld-Vlug M, Pring A, Schreyögg J, Ulrich CM, Verne J, Wunsch H, Emanuel EJ: Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries JAMA 315 (3): 272-283,2016.
Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, Herr HW, Lerner SP, Guzzo TJ, Malkowicz SB, Christodouleas JP: Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer Int J Radiat Oncol Biol Phys 95 (2): 703-6,2016.
Sharma S, Bekelman JE, Lin A, Lukens JN, Roman BA, Mitra N, Swisher-McClure S: Clinical Impact of Prolonged Diagnosis to Treatment Interval Among Patients with Oropharyngeal Squamous Cell Carcinoma Oral Oncology 56 : 17-24,2016.
Li J, Handorf E, Bekelman J, and Mitra N: Propensity score and doubly robust methods for estimating the effect of treatment on censored cost Statistics in Medicine 35 (12): 1985-99,2016.
View all publications